Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03215511
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
- NCT03215511 ↗
- Completed
- Bayer
- Focused
We haven't built an HCP commentary report on NCT03215511 (selitrectinib in previously treated NTRK fusion-positive solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03215511 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- Selitrectinib (BAY2731954)
- Arms
- Cancer participants <12 years · Experimental
- Cancer participants ≥12 years · Experimental
- Enrollment
- 81
- Primary outcomes
- Maximum tolerated dose (MTD)
- Recommended dose
- Sponsor
- Bayer
- Start
- Jul 3, 2017
- Primary completion
- Apr 11, 2022
- Results posted
- No
- Registry record
- NCT03215511 · updated Oct 30, 2024
Publications
linked from the registry- O'Reilly EM, Hechtman JF. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol. 2019 Nov 1;30(Suppl_8):viii36-viii40. doi: 10.1093/annonc/mdz385. Epub 2019 Dec 24. PubMed 31605106